Please wait



(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D 0001982476 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 03/11/2026 true 0001704287 095633608 Bluejay Diagnostics, Inc. 360 Massachusetts Avenue Suite 203 Acton MA 01720 Ross. D. Carmel, Esq. (212) 930-9700 1185 Avenue of the Americas 26th Floor New York NY 10036 0001982476 N Braeden Lichti PF N Z4 24500.00 11000.00 24500.00 11000.00 35500.00 N 3.65 IN Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 35,500 shares of Bluejay Diagnostics, Inc. ("Issuer") beneficially owned by Braeden Lichti, out of 972,000 shares of the Issuer's issued and outstanding shares of Common Stock, based on the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the SEC on March 6, 2026. 0002099270 N Northstrive Fund II LP WC N DE 0.00 11000.00 0.00 11000.00 11000.00 N 1.13 PN Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 11,000 shares of the Issuer beneficially owned by Northstrive Fund II LP, out of 972,000 shares of the Issuer's issued and outstanding shares of Common Stock as reported in the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the SEC on March 6, 2026. Common Stock, par value $0.0001 per share Bluejay Diagnostics, Inc. 360 Massachusetts Avenue Suite 203 Acton MA 01720 Mr. Braeden Lichti and Northstrive Fund (as defined below) previously filed a Schedule 13G on February 5, 2026 (the "Schedule 13G"). This Statement on Schedule 13D relates to the Common Stock of the Issuer and amends the Schedule 13G. The principal executive offices of the Issuer are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720. This Schedule 13D is filed jointly by Mr. Braeden Lichti and Northstrive Fund II LP (together with Braeden Lichti, the "Reporting Persons"). The shares of Common Stock are held jointly by the Reporting Persons. Mr. Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund, and he has voting and investment power of those shares of Common Stock held by Northstrive Fund. The address of each of the Reporting Persons is 120 Newport Center Drive, Newport Beach, CA 92660. Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company. Neither of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada. The information set forth in Item 4 is incorporated by reference herein. Northstrive Fund used working capital as the source of funds for its purchase of the Common Stock. Mr. Lichti used personal funds to purchase his shares of Common Stock. As of March 10, 2026, Northstrive Fund and Mr. Lichti beneficially owned 11,000 and 35,500 shares of Common Stock, respectively, representing 1.13% and 3.65% of the Issuer's issued and outstanding Common Stock. This percentage was calculated based on 972,000 shares of the Issuer's issued and outstanding shares of Common Stock, based on the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the SEC on March 6, 2026. This Schedule 13D is being filed to disclose Northstrive's Fund letter to the Board of Directors of the Issuer (the "Board") dated March 11, 2026 (the "Board Letter"). The Board Letter includes, among other things, Northstrive Fund's recommendations to the Board to review a potential biotechnology acquisition opportunity that Northstrive Fund has identified, in order to strengthen the Issuer's clinical pipeline and accelerate shareholder value creation, in Northstrive Fund's view. Northstrive Fund has requested to meet with the Board in the Board Letter. The Board Letter is filed herein as Exhibit A. As the Board Letter indicates an intent by the Reporting Persons with a purpose or effect to potentially change or influence control of the Issuer, the Reporting Persons have deemed it appropriate to amend the Schedule 13G by filing this Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate, which may include liquidation or further accumulation of shares. In addition, the Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) propose or consider one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D. See the information contained on the cover pages of this Schedule 13D, which is incorporated herein by reference. The percentage of Common Stock reported as beneficially owned by each Reporting Person is based on 972,000 shares of the Issuer's issued and outstanding shares of Common Stock, based on the Issuer's press release, filed as an exhibit to the Issuer's Current Report on Form 8-K with the SEC on March 6, 2026. Sole power to vote or to direct the vote: Braeden Lichti: 24,500 shares Northstrive Fund II LP: 0 shares Shared power to vote or to direct the vote: Braeden Lichti: 11,000 shares Northstrive Fund II LP: 11,000 shares Sole power to dispose or to direct the disposition of: Braeden Lichti: 24,500 shares Northstrive Fund II LP: 0 shares Shared power to dispose or to direct the disposition: Braeden Lichti: 11,000 shares Northstrive Fund II LP: 11,000 shares The information set forth in Item 3 above is incorporated herein by reference. Not applicable. 2/20/2026 The information in Items 3 and 4 is incorporated herein by reference. Exhibit A Letter to the Board of Directors of Issuer Exhibit B Transactions completed by Reporting Persons in the Common Stock Braeden Lichti /s/ Braeden Lichti Braeden Lichti 03/11/2026 Northstrive Fund II LP /s/ Braeden Lichti Braeden Lichti/Manager 03/11/2026